Kristina S Boye
Biographic Data
| ID | 3474538 |
|---|---|
| NAME | Kristina S Boye |
| GIVEN NAMES | Kristina S |
| FAMILY NAME | Boye |
| SIGNATURE | BOYE K S |
| AFFILIATIONS | Eli Lilly (United States) |
| ORCID | 0000-0002-5953-5929 |
| VERIFIED | Yes |
| TOTAL WORKS | 4 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 4 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2007 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
Prevalence of complications and comorbidities associated with obesity
In this claims study, hypertension and dyslipidemia were the leading comorbidities in people with obesity, with an increasing prevalence with age. The burden of cardiometabolic comorbidities among the younger age group suggested potential risk for early onset of CHD in later life. Understanding the range of obesity-related comorbidities seen in this claims data may encourage healthcare professionals and healthcare systems to systematically diagno…
Estimating meaningful change for The Impact of Weight on Self-Perception (IW-SP) questionnaire among people with type 2 diabetes
The MIC for the IW-SP for patients with T2D is a 25-point change on the transformed score
Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes
Results suggest that routes of administration cannot be compared using only the simplest descriptions (e.g., oral versus injectable). Dose frequency and specific details of the treatment process administration had an impact on patient preference and health state utilities. The utilities estimated in this study may be useful in cost-utility models comparing these treatments for T2D. Results also suggest that it may be helpful to consider patient p…
Utilities and disutilities for type 2 diabetes treatment-related attributes
No prominent works on this page.
Utilities and disutilities for type 2 diabetes treatment-related attributes
Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes
Results suggest that routes of administration cannot be compared using only the simplest descriptions (e.g., oral versus injectable). Dose frequency and specific details of the treatment process administration had an impact on patient preference and health state utilities. The utilities estimated in this study may be useful in cost-utility models comparing these treatments for T2D. Results also suggest that it may be helpful to consider patient p…
Estimating meaningful change for The Impact of Weight on Self-Perception (IW-SP) questionnaire among people with type 2 diabetes
The MIC for the IW-SP for patients with T2D is a 25-point change on the transformed score
Prevalence of complications and comorbidities associated with obesity
In this claims study, hypertension and dyslipidemia were the leading comorbidities in people with obesity, with an increasing prevalence with age. The burden of cardiometabolic comorbidities among the younger age group suggested potential risk for early onset of CHD in later life. Understanding the range of obesity-related comorbidities seen in this claims data may encourage healthcare professionals and healthcare systems to systematically diagno…
Medicine (3 works) · Diabetes mellitus (2 works) · Health Systems, Economic Evaluations, Quality of Life (2 works) · Internal Medicine (2 works) · Mathematics (2 works) · Obesity (2 works) · Obesity and Health Practices (2 works) · Type 2 diabetes (2 works) · Bariatric Surgery and Outcomes (1 work) · Biostatistics (1 work)